IGHE and neoplasm: Despite a slight decrease in FcεRI-expressing monocyte populations in patients compared to healthy subjects (Figure 4A), MOv18 IgE could direct both healthy volunteer- and ovarian cancer patient-derived monocytes to perform cytotoxic tumour cell killing (Figure 4B) [8,12].